Dermatologicals
Refine Search
Biotechnology
A second Phase III study from Incyte’s TRuE-AD clinical trial program in mild-to-moderate atopic dermatitis (AD) has met its primary endpoint. 19 February 2020
Generics
Dr Reddy’s Laboratories has entered into a definitive agreement with fellow Indian drugmaker Wockhardt to acquire select divisions of its branded generics business in India. 12 February 2020
Pharmaceutical
A look at why US drugmaker Eli Lilly is willing to spend more than $1 billion on the takeover of dermatology specialist Dermira. 11 February 2020
Biotechnology
Shares of US biotech Regeneron Pharmaceuticals were up 2.64% at $382.00 in early trading, after it reported financial results that beat expectations. 6 February 2020
Pharmaceutical
France’s largest pharma company was able to report a rise in sales in both its annual and quarterly financial results, presented on Thursday morning. 6 February 2020
Pharmaceutical
Spain's leading drugmaker Almirall is to work with Plug and Play, a health tech firm, to accelerate digital innovation in dermatology. 6 February 2020
Pharmaceutical
Major acquisitions are often announced in the first month of the year, with January 2019 seeing the $74 billion acquisition of Celgene by Bristol-Myers Squibb and Eli Lilly's $8 billion purchase of Loxo Oncology. 3 February 2020
Pharmaceutical
As part of competition requirements to consummate its $63 billion acquisition of Allergan, AbbVie has divested its gastrointestinal drug candidate brazikumab and cystic fibrosis drug Zenpep. Among research news, Acceleron saw its shares leap after it announced strong Phase III results for its pulmonary arterial hypertension drug sotatercept, and Incyte released encouraging top-line results from a Phase III study od ruxolitinib in atopic dermatitis. Regulatory news included, on Friday, Aimmune Therapeutics becoming the first company to gain US Food and Drug Administration approval for a peanut allergy treatment, to be marketed under the brand name Palforzia. 2 February 2020
Pharmaceutical
At its January meeting, the European Medicines Agency’s Committee for Medicinal Products for Human USE (CHMP) recommended approval of eight novel medicines and one biosimilar. The final decision of the European Commission on the marketing authorization is expected in the coming months. 31 January 2020
Biotechnology
A reverse merger between BioPharmX and Timber Pharmaceuticals has been agreed, giving the latter a quick and easy route to public markets to help develop its novel dermatology candidates. 29 January 2020
Biotechnology
Eli Lilly and its partner Incyte have announced positive Phase III results on baricitinib’s use alongside topical corticosteroids in moderate to severe atopic dermatitis (AD) that is not controlled with cyclosporine. 28 January 2020
Pharmaceutical
Incyte has announced positive top-line results from the Phase III TRuE-AD2 study of ruxolitinib cream in atopic dermatitis (AD). 28 January 2020
Biotechnology
The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) for a children’s eczema indication. 28 January 2020
Biotechnology
The Japanese health authorities have approved Cimzia (certolizumab pegol) to treat plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma for which existing treatment methods are not sufficiently effective. 28 January 2020
Biotechnology
Japan Tobacco and Torii Pharmaceutical have received manufacturing and marketing approval for Corectim Ointment 0.5% (delgocitinib; formerly JTE-052), a Janus kinase (JAK) inhibitor, for an indication of atopic dermatitis in Japan. 27 January 2020
Biotechnology
The Roivant Sciences company Dermavant has announced the appointment of Chris Chapman as its chief commercial officer. 22 January 2020
Pharmaceutical
At its January meeting, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) recommended that patients stop using Picato (ingenol mebutate), a gel for treating the skin condition actinic keratosis, while it continues its review of the medicine’s safety. 17 January 2020
Biotechnology
US drugmaker AbbVie’s Skyrizi (risankizumab) has met both primary and all ranked secondary endpoints, including superiority at week 52, in a comparison with Cosentyx (secukinumab) in moderate to severe plaque psoriasis. 15 January 2020
Biotechnology
Dermavant Sciences, a dermatology-focused subsidiary of Switzerland-based Roivant Sciences, has entered into a collaboration and license agreement with Japan Tobacco for exclusive rights to develop, register and market tapinarof in Japan for the treatment of dermatological diseases and conditions, including psoriasis and atopic dermatitis.
Along with 15 January 2020
Pharmaceutical
Among notable research news last week, Merck KGaA and Pfizer released new Phase III data for Bavencio in urothelial carcinoma, and Apellis Pharma reported strong results for its rare blood disorder candidate pegcetacoplan, seemingly besting Alexion’s Solaris. Dealing-making news featured Japan’s Chugai out-licensing its investigational cancer drug CKI27 to Verastem. Elsewhere, Blueprint Medicines gained earlier than expected Food and Drug Administration approval for Ayvakit (avapritinib for the treatment of gastrointestinal stromal tumors, and Eli Lilly announced a $1.1 billion takeover of dermatology specialist Dermira, along with its lead investigational candidate lebrikizumab. 12 January 2020
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Pharmaceutical
Beijing’s InnoCare Pharma has announced encouraging Phase II results for its novel TYK2 inhibitor, ICP-488, aimed at treating moderate-to-severe plaque psoriasis. 10 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze